YAP1的表达与小细胞肺癌的生存和免疫抑制有关
Peixin Chen1,2, Chenglong Sun3, Hao Wang1,2
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai, 200433, People's Republic of China.
在小细胞肺癌 (SCLC) 中准YAP1提供了一种增强免疫疗法的新策略. 在SCLC-Y亚型中阻断YAP1可以改善抗瘤免疫反应和患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 小细胞肺癌 (SCLC) 是高度恶性和异质的,限制了免疫治疗的疗效.
- 需要新的组合策略来改善SCLC治疗结果.
- SCLC表现出显著的分子异质性,需要特定于亚型的治疗方法.
研究的目的:
- 根据关键转录因子表达来分类SCLC亚型.
- 研究YAP1在SCLC免疫逃避和治疗反应中的作用.
- 评估YAP1阻塞作为一种加强SCLC免疫治疗的策略.
主要方法:
- 基于免疫光的100名SCLC患者的SCLC-A,SCLC-N,SCLC-P和SCLC-Y亚型的分类.
- 对临床结果,瘤微环境和各亚型免疫治疗敏感性的分析.
- 在体外实验中评估YAP1阻断对癌细胞和免疫细胞的影响.
主要成果:
- SCLC-Y亚型 (高YAP1表达) 显示了最糟糕的临床结果.
- 在SCLC-Y瘤中,PD-L1高, stromal评分高,T细胞功能受损.
- YAP1的上调抑制了T细胞的激活,并促进了免疫逃避.
- 在实验室中YAP1阻断增强了细胞灭亡,免疫细胞增殖和T细胞激活.
结论:
- SCLC表现出不同的分子亚型,预后和免疫治疗反应各不相同.
- 这种SCLC-Y亚型的特征是YAP1驱动的免疫逃避.
- 向YAP1是一个有希望的策略,以克服SCLC-Y患者的免疫疗法耐药性.
更多相关视频
09:55All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
相关概念视频
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Survival Analysis
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
